Do analysts rate ICG or QCLS?

Intchains Group presently has a consensus price target of $2.50, indicating a potential upside of 159.61%. Given Intchains Group's stronger consensus rating and higher probable upside, analysts plainly believe Intchains Group is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intchains Group 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ICG or QCLS?

In the previous week, Mymd Pharmaceuticals had 1 more articles in the media than Intchains Group. MarketBeat recorded 3 mentions for Mymd Pharmaceuticals and 2 mentions for Intchains Group. Intchains Group's average media sentiment score of 0.94 beat Mymd Pharmaceuticals' score of 0.93 indicating that Intchains Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intchains Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate QCLS or TACT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TransAct Technologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer QCLS or TACT?

In the previous week, TransAct Technologies had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 4 mentions for TransAct Technologies and 3 mentions for Mymd Pharmaceuticals. TransAct Technologies' average media sentiment score of 1.18 beat Mymd Pharmaceuticals' score of 0.93 indicating that TransAct Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransAct Technologies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend QCLS or VTIX?

Virtuix has a consensus target price of $11.00, suggesting a potential upside of 1,043.45%. Given Virtuix's stronger consensus rating and higher probable upside, analysts clearly believe Virtuix is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virtuix 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is QCLS or VTIX more profitable?

Virtuix's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -91.64% -47.48% Virtuix N/A N/A N/A

Does the media favor QCLS or VTIX?

In the previous week, Virtuix had 3 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 6 mentions for Virtuix and 3 mentions for Mymd Pharmaceuticals. Virtuix's average media sentiment score of 0.99 beat Mymd Pharmaceuticals' score of 0.93 indicating that Virtuix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Virtuix 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate FOXX or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foxx Development 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer QCLS or EBON?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ebang International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, QCLS or EBON?

Mymd Pharmaceuticals has higher earnings, but lower revenue than Ebang International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mymd Pharmaceuticals N/A N/A -$11.63M -$3.48 N/A Ebang International $6.88M 2.01 -$14.09M N/A N/A

Is QCLS or EBON more profitable?

Ebang International's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -91.64% -47.48% Ebang International N/A N/A N/A

Mymd Pharmaceuticals (QCLS) Competitors

$0.48 -0.08 (-14.66%)

As of 12:44 PM Eastern

Compare

QCLS vs. ICG, TACT, VTIX, FOXX, and EBON

Should you buy Mymd Pharmaceuticals stock or one of its competitors? Mymd Pharmaceuticals's main competitors and comparable companies include Intchains Group (ICG), TransAct Technologies (TACT), Virtuix (VTIX), Foxx Development (FOXX), and Ebang International (EBON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "technology hardware, storage & peripherals" industry.

How does Mymd Pharmaceuticals compare to Intchains Group?

Intchains Group (NASDAQ:ICG) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap technology companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Mymd Pharmaceuticals has a net margin of 0.00% compared to Intchains Group's net margin of -24.68%. Intchains Group's return on equity of -5.29% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intchains Group	-24.68%	-5.29%	-5.08%
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%

Intchains Group has higher revenue and earnings than Mymd Pharmaceuticals. Intchains Group is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intchains Group	$56.41M	1.04	-$6.80M	-$0.12	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A

Intchains Group has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

In the previous week, Mymd Pharmaceuticals had 1 more articles in the media than Intchains Group. MarketBeat recorded 3 mentions for Mymd Pharmaceuticals and 2 mentions for Intchains Group. Intchains Group's average media sentiment score of 0.94 beat Mymd Pharmaceuticals' score of 0.93 indicating that Intchains Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intchains Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intchains Group presently has a consensus price target of $2.50, indicating a potential upside of 159.61%. Given Intchains Group's stronger consensus rating and higher probable upside, analysts plainly believe Intchains Group is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intchains Group	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Intchains Group beats Mymd Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to TransAct Technologies?

Mymd Pharmaceuticals (NASDAQ:QCLS) and TransAct Technologies (NASDAQ:TACT) are both small-cap technology companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TransAct Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Mymd Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market. Comparatively, TransAct Technologies has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 74.5% of TransAct Technologies shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by insiders. Comparatively, 19.2% of TransAct Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Mymd Pharmaceuticals has a net margin of 0.00% compared to TransAct Technologies' net margin of -0.75%. TransAct Technologies' return on equity of -1.25% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%
TransAct Technologies	-0.75%	-1.25%	-0.85%

In the previous week, TransAct Technologies had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 4 mentions for TransAct Technologies and 3 mentions for Mymd Pharmaceuticals. TransAct Technologies' average media sentiment score of 1.18 beat Mymd Pharmaceuticals' score of 0.93 indicating that TransAct Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransAct Technologies	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransAct Technologies has higher revenue and earnings than Mymd Pharmaceuticals. TransAct Technologies is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A
TransAct Technologies	$51.48M	1.02	-$1.24M	-$0.04	N/A

Summary

TransAct Technologies beats Mymd Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Virtuix?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Virtuix (NASDAQ:VTIX) are both small-cap technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

In the previous week, Virtuix had 3 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 6 mentions for Virtuix and 3 mentions for Mymd Pharmaceuticals. Virtuix's average media sentiment score of 0.99 beat Mymd Pharmaceuticals' score of 0.93 indicating that Virtuix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Virtuix	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Virtuix has a consensus target price of $11.00, suggesting a potential upside of 1,043.45%. Given Virtuix's stronger consensus rating and higher probable upside, analysts clearly believe Virtuix is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virtuix	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virtuix's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%
Virtuix	N/A	N/A	N/A

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Comparatively, 28.6% of Virtuix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Mymd Pharmaceuticals has higher earnings, but lower revenue than Virtuix. Virtuix is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A
Virtuix	$3.99M	7.23	-$16.80M	-$0.70	N/A

Summary

Virtuix beats Mymd Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Foxx Development?

Foxx Development (NASDAQ:FOXX) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap technology companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foxx Development	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mymd Pharmaceuticals has a net margin of 0.00% compared to Foxx Development's net margin of -79.80%. Foxx Development's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foxx Development	-79.80%	N/A	-59.35%
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%

Foxx Development has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

60.4% of Foxx Development shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 31.6% of Foxx Development shares are held by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Foxx Development has higher revenue and earnings than Mymd Pharmaceuticals. Foxx Development is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foxx Development	$59.54M	0.30	-$9.02M	-$6.87	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A

In the previous week, Mymd Pharmaceuticals had 2 more articles in the media than Foxx Development. MarketBeat recorded 3 mentions for Mymd Pharmaceuticals and 1 mentions for Foxx Development. Foxx Development's average media sentiment score of 1.87 beat Mymd Pharmaceuticals' score of 0.93 indicating that Foxx Development is being referred to more favorably in the media.

Company	Overall Sentiment
Foxx Development	Very Positive
Mymd Pharmaceuticals	Positive

Summary

Foxx Development and Mymd Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Ebang International?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Ebang International (NASDAQ:EBON) are both small-cap technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Mymd Pharmaceuticals has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market. Comparatively, Ebang International has a beta of 2.99, meaning that its share price is 199% more volatile than the broader market.

In the previous week, Mymd Pharmaceuticals had 2 more articles in the media than Ebang International. MarketBeat recorded 3 mentions for Mymd Pharmaceuticals and 1 mentions for Ebang International. Ebang International's average media sentiment score of 1.87 beat Mymd Pharmaceuticals' score of 0.93 indicating that Ebang International is being referred to more favorably in the news media.

Company	Overall Sentiment
Mymd Pharmaceuticals	Positive
Ebang International	Very Positive

Ebang International's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%
Ebang International	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ebang International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 1.1% of Ebang International shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by insiders. Comparatively, 25.4% of Ebang International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Mymd Pharmaceuticals has higher earnings, but lower revenue than Ebang International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A
Ebang International	$6.88M	2.01	-$14.09M	N/A	N/A

Summary

Ebang International beats Mymd Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Mymd Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QCLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QCLS vs. The Competition

Export

Metric	Mymd Pharmaceuticals	Technology Hardware, Storage & Peripherals Industry	Technology Sector	NASDAQ Exchange
Market Cap	$3.93M	$115.29B	$29.25B	$14.37B
Dividend Yield	N/A	1.63%	2.73%	11.71%
P/E Ratio	-0.14	27.63	76.35	25.33
Price / Sales	N/A	96.09	585.66	97.70
Price / Cash	N/A	21.04	46.59	34.96
Price / Book	0.09	7.56	7.69	6.19
Net Income	-$11.63M	$3.49B	$705.00M	$358.05M
7 Day Performance	-75.23%	-6.33%	-1.75%	-1.55%
1 Month Performance	-82.74%	-8.56%	-4.64%	-3.54%
1 Year Performance	N/A	61.31%	176.49%	5.78%

Mymd Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QCLS Mymd Pharmaceuticals	0.4318 of 5 stars	$0.48 -14.7%	N/A	N/A	$3.93M	N/A	N/A	6	News Coverage Gap Up High Trading Volume
ICG Intchains Group	3.5036 of 5 stars	$0.99 +5.1%	$2.50 +153.4%	-47.3%	$57.01M	$31.58M	N/A	133
TACT TransAct Technologies	1.3626 of 5 stars	$5.16 -0.6%	N/A	+12.5%	$53.58M	$52.99M	N/A	120	News Coverage Positive News
VTIX Virtuix	2.5303 of 5 stars	$1.31 flat	$11.00 +739.7%	N/A	$39.26M	$4.25M	N/A	39
FOXX Foxx Development	1.0057 of 5 stars	$2.71 +3.4%	N/A	-45.3%	$18.45M	$65.92M	N/A	N/A	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QCLS) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. ICG, TACT, VTIX, FOXX, and EBON

How does Mymd Pharmaceuticals compare to Intchains Group?

Summary

How does Mymd Pharmaceuticals compare to TransAct Technologies?

Summary

How does Mymd Pharmaceuticals compare to Virtuix?

Summary

How does Mymd Pharmaceuticals compare to Foxx Development?

Summary

How does Mymd Pharmaceuticals compare to Ebang International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. ICG, TACT, VTIX, FOXX, and EBON

How does Mymd Pharmaceuticals compare to Intchains Group?

Do institutionals & insiders believe in ICG or QCLS?

Is ICG or QCLS more profitable?

Which has stronger valuation & earnings, ICG or QCLS?

Which has more risk and volatility, ICG or QCLS?

Does the media favor ICG or QCLS?

Do analysts rate ICG or QCLS?

Summary

How does Mymd Pharmaceuticals compare to TransAct Technologies?

Do analysts rate QCLS or TACT?

Which has more risk and volatility, QCLS or TACT?

Do institutionals & insiders believe in QCLS or TACT?

Is QCLS or TACT more profitable?

Does the media prefer QCLS or TACT?

Which has better earnings and valuation, QCLS or TACT?

Summary

How does Mymd Pharmaceuticals compare to Virtuix?

Does the media favor QCLS or VTIX?

Do analysts recommend QCLS or VTIX?

Is QCLS or VTIX more profitable?

Do institutionals and insiders have more ownership in QCLS or VTIX?

Which has better earnings and valuation, QCLS or VTIX?

Summary

How does Mymd Pharmaceuticals compare to Foxx Development?

Do analysts rate FOXX or QCLS?

Is FOXX or QCLS more profitable?

Which has more risk & volatility, FOXX or QCLS?

Do institutionals and insiders believe in FOXX or QCLS?

Which has better valuation and earnings, FOXX or QCLS?

Does the media prefer FOXX or QCLS?

Summary

How does Mymd Pharmaceuticals compare to Ebang International?

Which has more risk & volatility, QCLS or EBON?

Does the media refer more to QCLS or EBON?

Is QCLS or EBON more profitable?

Do analysts prefer QCLS or EBON?

Do institutionals & insiders believe in QCLS or EBON?

Which has preferable earnings and valuation, QCLS or EBON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools